Content
All Posts > Content under Pharma/Biotech
Cannabis Central: 84% Of The Pot Stock Index Constituents Declined On Wednesday
Article By:
Lorimer Wilson
Read
Thursday, August 20, 2020 5:00 AM EDT
84% of the 25 pure-play Pot Stock Index constituents declined on Wednesday causing the PSI to decline 2.6% resulting in 3 of the 4 associated categories declining. In addition, 3 constituents advanced and 1 had no change in price.
Market Briefing For Thursday, August 20
Article By:
Gene Inger
Read
Thursday, August 20, 2020 2:50 AM EDT
Health heaviness holds the Fed to a defensive stance while they express concern indirectly about systemic stability, and even higher yields 'pulling' policy shifts later in the course of developments; or sort of hinted-at by their oblique comments.
Cannabis Central: Pure-Play Pot Stock Index Declined On Tuesday
Article By:
Lorimer Wilson
Read
Wednesday, August 19, 2020 10:43 AM EDT
The Pot Stock Index of the 25 pure-play cannabis stocks that trade for more than US$1/share declined 1.9% on Tuesday. 11 of the constituents advanced, 13 declined, 1 had no change and 3 of the 4 associated sector categories declined.
Galapagos Sinks After FDA Issues Complete Response Letter To Partner Gilead
Market Briefing For Tuesday, August 18
Article By:
Gene Inger
Read
Tuesday, August 18, 2020 2:01 AM EDT
Circumstances go well beyond 'Covid' with respect to the market. Assumptions that a Biden/Harris ticket means centrist policies is what the market wants to see for now, whether that's truly their perspective or not.
FDA Places Partial Clinical Hold On Applied Therapeutics Galactosemia Study
Article By:
The Fly
Read
Monday, August 17, 2020 8:56 AM EDT
Applied Therapeutics received a letter from the Food and Drug Administration that placed a partial clinical hold on the ACTION-Kids Study and requested that the company provide the FDA additional technical information.
In this article: APLT
So Far Not A Year For The Dogs Of The Dow
Article By:
David Templeton
Read
Monday, August 17, 2020 7:02 AM EDT
This year has not been a good one for the Dogs of the Dow strategy. A number of reasons can be cited, like energy sector weakness and both Chevron and Exxon Mobil included in the strategy this year or Cisco and IBM a part of the Dow Dog portfolio.
Sanofi Acquires Principia Biopharma For $100 Per Share Or $3.68B
Week In Review: $2.5 Billion In Deals Including LianBio's Initial $719 Million In In-Licensings
Article By:
ChinaBio® Today
Read
Saturday, August 15, 2020 1:13 PM EDT
LianBio, a new Princeton-Shanghai company, acquired China rights to two BridgeBio oncology assets in a $531.5 million agreement. BridgeBio will receive $26.5 million in upfront payments, plus up to $505 million in future milestones.